Oxford Nanopore at AGBT 2026 General Meeting

Dr Lakmal Jayasinghe is the Chief Scientific Officer at Oxford Nanopore Technologies, where he leads the company's scientific vision, driving groundbreaking research and development to advance innovation in nanopore sequencing and its transformative applications.

Before joining Oxford Nanopore in 2006, Dr Jayasinghe completed his PhD in chemical biology at the University of Oxford, where he was a member of the Hagan Bayley group. His research focused on the study and engineering of nanopores using genetic and chemical approaches, providing him with a deep understanding of nanopore technology.

During his tenure at Oxford Nanopore, the company has achieved unprecedented advancements in sequencing accuracy, throughput, and versatility, enabling global researchers to explore applications spanning genomics, transcriptomics, and epigenetics. Lakmal has also championed advancements in direct RNA sequencing, revolutionising the study of native RNA molecules and their modifications, both in academic research and the biopharma industry. Over his time with Oxford Nanopore, Lakmal has held several leadership positions, including Senior Scientist, Principal Scientist, and Vice President, where he has led interdisciplinary R&D teams in biologics.

Marilyn M. Li, M.D. is a Professor of Pathology and Pediatrics, Vice Chief of Division of Genomic Diagnostics, Director of Cancer Genomic Diagnostics at Children’s Hospital of Philadelphia, University of Pennsylvania, Perelman School of Medicine. Dr. Li is board-certified by the American Board of Medical Genetics and Genomics. Her primary research interest is the clinical application of high-throughput multi-omics technologies in cancer research and clinical diagnosis to facilitate precision cancer care. She is the recipient of many prestigious awards and has published over 150 peer-reviewed articles and has given over 100 invited presentations and grand rounds nationally and worldwide.

Mark Drost works as a Clinical Laboratory Geneticist at the Erasmus MC. His focus lies in the development and implementation of new genetic technologies focusing on faster and more informative diagnostic workflows.